[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543435":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":29,"locations":39,"responsibleParty":55,"collaborators":57,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Universidade Nova de Lisboa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intermediate AMD",null,"Subjects over 55 years old with drusen secondary to intermediate AMD",[13],"Diagnostic Test: Orthoptic assessment (Outcome measure)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Orthoptic assessment (Outcome measure)","The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).",[9],[21,25],{"name":22,"affiliation":23,"role":24},"Rita Flores, MD","Centro Hospitalar Universitário de Lisboa Central, iNOVA4Health Nova Medical School, Universidade Nova de Lisboa","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":27,"role":28},"Sandra Tenreiro, PhD","iNOVA4Health Nova Medical School, Universidade Nova de Lisboa","STUDY_CHAIR",[30,35],{"name":22,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","00351218841000","21355","ritamariaflores@gmail.com",{"name":26,"role":31,"phone":36,"phoneExt":37,"email":38},"00351218803100","26025","stenreiro@nms.unl.pt",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Ophthalmology Service, Centro Hospitalar de Lisboa Central EPE","RECRUITING","Lisbon","1150-199","Portugal","PT",{"type":48,"coordinates":49},"Point",[50,51],-9.1498,38.72509,{"lat":51,"lon":50},[54],{"name":22,"role":31,"phone":32,"phoneExt":33,"email":34},{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[58,61,63],{"name":59,"class":60},"iNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, UNL","UNKNOWN",{"name":62,"class":6},"Centro Hospitalar de Lisboa Central",{"name":64,"class":6},"Centro Hospitalar De São João, E.P.E.","100543435","intermediate-age-related-macular-degeneration---multimodal-analysis-and-longitudinal-study-100543435",false,"NCT06355830","Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study","Imaging4iAMD","Inclusion Criteria:\n\n* To verify the existence of drusen secondary to intermediate AMD; Soft, cuticular and reticular pseudo-drusen will be considered.\n* Accept and sign the consent.\n\nExclusion Criteria:\n\n* Patients are excluded if it is not possible to obtain good quality CFP, SD-OCT, OCT-A images, if refractive error is ≥±6D or if there is any evidence of accumulation of extracellular fluid, haemorrhage, exudates or fibrosis.\n* Additional exclusion criteria included any history of retinal surgery including laser treatment, signs of diabetic retinopathy, history of retinal vascular occlusion, history of anti-VEGF treatment in the study eye or any signs or history of hereditary retinal or macular dystrophy.","ALL","55 Years","95 Years",{"count":76,"type":77},150,"ESTIMATED","4 Years","OBSERVATIONAL","Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD.\n\nRecruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC.\n\nPrimary outcome: Identifying imaging predictors of iAMD progression.",[82],"Age-Related Macular Degeneration",[84,85,86,87],"Intermediate AMD","Progression Biomarkers","Late AMD","SD-OCT","2024-04-03",{"date":90,"type":91},"2024-04-09","ACTUAL",{"date":93,"type":91},"2019-01-02",{"date":95,"type":77},"2026-06",{"name":5,"class":6},1]